Numerous investigations into m6A modification have elucidated its significant association with resistance to immune checkpoint inhibitors, particularly those targeting the PD-1/PD-L1 axis.222,629,630 The overexpression of METTL3 in thyroid cancer cells can enhance the efficacy of anti-PD-1 therapy. Here, METTL3 is linked to thyroid cancer.